Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer

Author：          

Publisher： Spandidos Publications

ISSN： 1792-0981

Source： Experimental and Therapeutic Medicine, Vol.3, Iss.1, 2012-01, pp. : 66-71

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

By Dubsky P.   Filipits M.   Jakesz R.   Rudas M.   Singer C. F.   Greil R.   Dietze O.   Luisser I.   Klug E.   Sedivy R.   Bachner M.   Mayr D.   Schmidt M.   Gehrmann M. C.   Petry C.   Weber K. E.   Kronenwett R.   Brase J. C.   Gnant M.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 640-647

Oxford University Press

Access to resources Recommend Favorite

Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics

By Lips E.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 827-836

Springer Publishing Company

Access to resources Recommend Favorite

Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer

By Chen Xiaosong   Ye Guolin   Zhang Chenfang   Li Xinzheng   Chen Yiding   Xie Xiaohong   Zheng Hong   Cao Yali   Wu Kejin   Ni Duo   Tang Jinhai   Wei Ziguo   Shen Kunwei  

Breast Cancer Research and Treatment, Vol. 142, Iss. 3, 2013-12 ,pp. : 549-558

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer

By                

Oncology Letters, Vol. 7, Iss. 3, 2014-01 ,pp. : 663-668

Spandidos Publications

Access to resources Recommend Favorite

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

By Eiermann W.   Rezai M.   Kmmel S.   Khn T.   Warm M.   Friedrichs K.   Schneeweiss A.   Markmann S.   Eggemann H.   Hilfrich J.   Jackisch C.   Witzel I.   Eidtmann H.   Bachinger A.   Hell S.   Blohmer J.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 618-624

Oxford University Press

Access to resources Recommend Favorite